I Know First Reviews: June 24th, 2015

I Know First Reviews

The stocks selected here are the top performing stocks from I Know First: Daily Market Forecast’s June 1st, 2015 stock forecast titled “Best Biotech Stocks Based on Algorithms: Up To 16.62% Return in 7 Days“.

This forecast is part of the “Tech Stocks” package, as one of I Know First’s quantitative investment solutions. The “I Know First Average” return for the long position was 9.12% over 7 days versus the S&P 500’s return of 1.37% over the same time period.

I Know First Review

 

Learn how to read the predictions: Instructions

Learn how to strategize with the forecast: Algorithmic Trading Strategies 

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.

 

 

shire-plc-logo

Signal: 24.21

Predictability: 0.14

Return: 2.47%

Shire PLC (SHPG)  is a biotech company with a focus on developing and delivering innovative medicines for patients with rare diseases and other specialty conditions.  They are also very active in the field of ADHD therapies.  The company had a signal strength of 24.21 and a predictability indicator of 0.14. In accordance with the algorithm’s prediction, stock price increased 2.47%.

With $4.54 billion in operating cash flow and a current ratio of 0.52, Shire has handled the recent controversy over ADHD drug use and abuse well.  Their future plans to prevent unneeded prescriptions and medication abuse will help them weather the storm as news of prescription abuse and excessive prescriptions become a hot topic.

 


mack

Signal: 22.98

Predictability: 0.06

Return: 12.55%

Merrimack Pharmaceuticals (MACK) commercializes innovative cancer  medicines and pairs them with complementary diagnostics. The Company uses a systems biology-based approach to study the underlying biology of cancer. The company had a signal strength of 22.98 and a predictability indicator of 0.06. In accordance with the algorithm’s prediction, stock prices increased by 12.55%.

Stock prices rose immediately following Merrimack’s announcement of John M. Dineen’s election to its Board of Directores June 15th.  Dineen’s strong performance history as CEO of GE Healthcare bodes well for the future growth and sustainability of the company.

 

geva

Signal: 21.03

Predictability: 0.17

Return: 7.1%

Synageva BioPharma Corp (GEVA) creates an array of therapies for rare and devastating diseases.  The company had a signal strength of 21.03 and a predictability indicator of 0.17. In accordance with the algorithm’s prediction, stock prices increased by 7.1%.

As previously announced, Synageva officially became a wholly owned subsidiary of Alexion on June 23rd.  This drove up the both trade volume and price.


bmrn

Signal: 17.79

Predictability: 0.45

Return: 14.73%

BioMarin Pharmaceutical Inc. (BMRN) develops and commercializes promising new therapeutics to patients with rare genetic diseases. Apart from their multiple clinical and pre-clinical product candidates, BioMarin has brought to market an impressive 5 products.  The company had a signal strength of 17.79 and a predictability indicator of 0.45. In accordance with the algorithm’s prediction, stock prices increased by 14.73%.

This stock’s strong performance follows the announcement of positive results from Phase 2 of a drug trial for achondroplasia, the most common form of dwarfism.  If these results are replicated in later phase trials, BioMarin will be on track to have the first approved drug to treat achondroplasia.


vrtx

Signal: 20.05

Predictability: 0.09

Return: 3.76%

Vertex Pharmaceuticals Incorporated (VRTX) is an international pharmaceutical company with a righ history of collaborative breakthroughs in research and treatment of diseases such as hepatitis C, HIV, and cystic fibrosis.  The company had a signal strength of 20.05 and a predictability indicator of 0.09. In accordance with the algorithm’s prediction, stock prices increased by 3.76%.

The company’s positive return follows the data revealed at a presentation at the European Cystic Fibrosis Society Conference, in which Vertex announced continued positive results in a Phase 3 study for the treatment of cystic fibrosis.  Vertex also announced the addition of a new board member, Dr. Sangeeta Bhatia, a prominent physician, engineer, and professor whose expertise will help the company continue to thrive.

 

exel 

Signal: 17.79

Predictability: 0.45

Return: 10.39%

Exelixis (EXEL) is a biopharmaceutical company specializing in molecular improvements to current cancer treatments.   Developed in its own lab, Exelixis owns the rights to the compound cabozantinib which it uses to attract collaborative partners and form strategic alliances with other pharmaceutical companies.  The company had a signal strength of 17.79 and a predictability indicator of 0.45. In accordance with the algorithm’s prediction, the stock price increased 10.39%.

Following a drop in stock price in the fourth quarter of 2014, stock prices began rising in January and have not stopped.  This rise parallels the ongoing positive results from its two-stage Phase 2 investigator-sponsored trial evaluating cabozantinib in patients with advanced RET-rearranged lung cancers.


alny

Signal : 17.36

Predictability : 0.14

Return: 6.49%

Alnylam Pharmaceuticals (ALNY) is the biopharmaceutical company that discovered the proper technique to apply RNAi as therapy. A worldwide leader in RNAi therapeutics, Alnylam studies innovative treatments that use genetically defined targets to treat diseases that currently have limited treatment options.  The company had a signal strength of 17.36 and a predictability indicator of 0.14. In accordance with the algorithm’s prediction, the stock price increased 6.49%.

These positive returns follow the news that Alnylam’s fourth RNAi therapeutic program has continued to yield promising results throughout its clinical trial, driving up their stock price.

 

KITE PHARMA, INC. LOGO

Signal: 15.16

Predictability: 0.13

Return: 12.79%

Kite Pharma (KITE) is a newer biopharmaceutical company focusing on developing cancer fighting products that harness the power of the patient’s own T-cells.    The company had a signal strength of 15.16 and a predictability indicator of 0.13. In accordance with the algorithm’s prediction, the stock price increased 12.79%.

High returns follow the news that Kite Pharma is collaborating on a project to use their T-cell method of cancer treatment on HPV, specifically the type that causes cervical cancer.  Although this innovative technique has a promising future, it remains under the radar, making this a bullish company to invest in.

 

fbiox

Signal : 13.20

Predictability : 0.14

Return: 4.31%

Fidelity Select Biotechnology (FBIOX), a healthcare mutual fund, had a signal strength of 13.20 and a predictability indicator of 0.41. In accordance with the algorithm’s prediction, the stock price increased by 4.31%.  While most healthcare mutual funds have predictable returns affected by changes such as the Affordable Care Act and other issues in the healthcare sector, Fidelity Select Biotechnology Portfolio keeps most of its assets in companies involved in research, development, and manufacture of various biotechnological products.  Therefore, this portfolio depends more on the economic strength of the companies, as well as their research and discoveries.

 

 

xoma

Signal: 12.96

Predictability: 0.15

Return: 16.62%

XOMA Corporation (XOMA) is a California based biotechnology leader in the discovery and development of therapeutic antibodies.  XOMA had a signal strength of 12.96 and a predictability indicator of 0.15. In accordance with the algorithm’s prediction, XOMA stock prices increased by 16.62%.

XONA is making great strides in developing a therapy that has the potential to address a significant unmet therapeutic need for certain rare medical conditions associated with hyperinsulinism in a safe and effective manner.  Recognition of this research was proven when they were granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of congenital hyperinsulinism on June 16th.

 

Business Disclosure: I Know First Research is the analytic branch of I Know First, a financial startup company that specializes in quantitatively predicting the stock market. We did not receive compensation for this article, and we have no business relationship with any company whose stock is mentioned in this article. Read More From I Know First Research:

  • Electric Buses Vs. Fuel Cell Buses: Plug Power Has A Stake In The Winner (View)
  • Why BlackBerry Holds Long-Term Value For Investors (View)
  • Tata Motors Is An Attractive Opportunity: An Algorithmic Analysis (View)
  • Applied Material’s Venture Group Invests Into UV LED, An Interesting Portfolio Expansion With Growth Potential (View)
  • Can Apollo Fight Online Education Any Longer? (View)